Abstract: A method is provided for manufacturing an aqueous formulation of a manganese-containing coordination complex, by combining a source of the manganese-containing coordination complex with a source of chloride anion in an aqueous solution, and simultaneously with or following combination of the source of chloride anion and the source of manganese-containing coordination complex in the aqueous solution, providing a source of a dianion to the aqueous solution to form the aqueous formulation.

Abstract: A skin treatment applicator device includes an elastomeric band which can be extended across a user's back. The elastomeric band is stretchable to such that tension in the elastomeric band enables the elastomeric band to be compressed against the user's back. A block is attached to the elastomeric band and the block is placed against the user's back when the user stretches the elastomeric band across their back. A plurality of bristles is each attached to the block thereby enabling the plurality of bristles to be pressed against the user's back when the user stretches the elastomeric band across their back. Each of the plurality of bristles is comprised of a fluid impermeable material thereby enabling the plurality of bristles to spread a fluid skin treatment across the user's back.

Abstract: Disclosed are pharmaceutical compositions comprising a salt of a compound having the formula: and one or more excipients, wherein the pharmaceutical composition avoids inducing disproportionation of the salt of the compound.

Abstract: A method is provided for manufacturing an aqueous formulation of a manganese-containing coordination complex, by combining a source of the manganese-containing coordination complex with a source of chloride anion in an aqueous solution, and simultaneously with or following combination of the source of chloride anion and the source of manganese-containing coordination complex in the aqueous solution, providing a source of a dianion to the aqueous solution to form the aqueous formulation.

Abstract: The present invention provides 16 new crystalline forms of tiagabine hydrochloride.

Abstract: The present invention provides 24 new forms of tiagabine, including 22 new crystalline forms of tiagabine and its salts, an amorphous form of tiagabine free base, and a cocrystal form of tiagabine hydrochloride with 2-furancarboxylic acid. The present invention further provides a process for preparing each of the new tiagabine forms. The present invention further provides a pharmaceutical composition containing at least one of the new tiagabine forms, and a process for the preparation thereof. The present invention further provides a method of treating a disease related to GABA uptake in a mammal, comprising the step of administering to the mammal a therapeutically effective amount of at least one of the new tiagabine forms.